provides entered into an contract with a leading commercial manufacturer to create its FDA-accepted MuGard for UNITED STATES distribution. A number of U.S. Marketplace seeding research could begin as early as Q4 2009, the ongoing company says. In a assessment of cancer sufferers receiving regular oral mucositis treatment with those patients receiving MuGard , MuGard provides been proven to significantly decrease the incidence and severity of the debilitating side effect of radiation treatment and chemotherapy. Related StoriesOvarian cancers patients with a history of oral contraceptive make use of have better outcomesMD Anderson research reveals why chemotherapy medicines not effective for many pancreatic cancer patientsCrucial change in single DNA foundation predisposes children to intense form of cancerAccess provides contracted with Accupac, Inc.For the first one fourth of 2012, price of revenue was $23.6 million in comparison to $23.9 million in the same period of 2011. Product gross margin was 59.7 percent, when compared with 64.6 percent in the same amount of 2011. Cost of services and additional was $3.8 million compared to $3.2 million in the same amount of 2011. For the first quarter of 2012, operating expenditures had been $41.3 million as compared to operating expenditures of $43.5 million in the same amount of 2011. The 2012 expenditures included $1.3 million in acquisition and associated legal expenses. Through the first one fourth we began to realize the advantages of reorganizing the business with a business device focus and a strengthened commercial group.